CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients

Leukemia

Volumn 28, Issue 7, 2014, Pages 1494-1500

  Tefferi, A ^a   Guglielmelli, P ^b   Lasho, T L ^a   Rotunno, G ^b   Finke, C ^a   Mannarelli, C ^b   Belachew, A A ^a   Pancrazzi, A ^b   Wassie, E A ^a   Ketterling, R P ^a   Hanson, C A ^a   Pardanani, A ^a   Vannucchi, A M ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; CALRETICULIN; HEMOGLOBIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKEMIA FREE SURVIVAL; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SPLICEOSOME; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; CALRETICULIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PRIMARY MYELOFIBROSIS; PROGNOSIS; REPRESSOR PROTEINS;

EID: 84904056081     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.57     Document Type: Article

References (24)

1. Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014 28 50-58.
2. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. New Engl J Med 2011 364 2496-2506.
3. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013 27 1861-1869.
4. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014 28 1407-1413.
5. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 2013 369 2391-2405.
6. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013 369 2379-2390.
7. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis clinical, cytogenetic and molecular comparisons. Leukemia 2014 28 1472-1477.
8. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013 e-pub ahead of print 26 December 2013.
9. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013 e-pub ahead of print 23 December 2013.
10. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011 29 392-397.
11. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009 113 2895-2901.
12. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia rationale and important changes. Blood 2009 114 937-951.
13. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis a single center study of 433 patients. Leukemia 2011 25 82-88.
14. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013 27 1504-1510.
15. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia prevalence, clinical correlates, and prognostic relevance. American Journal of Hematology 2013 88 201-206.
16. Tefferi A, Finke CM, Lasho TL, Wassie EA, Knudson R, Ketterling RP et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2013 28 431-433.
17. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012 120 4168-4171.
18. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012 26 475-480.
19. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis critical assessment of value and limitations. Leukemia 2011 25 218-225.
20. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010 115 1703-1708.
21. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis a Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011 118 4595-4598.
22. Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest 2013 123 4627-4640.
23. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013 210 2641-2659.
24. Eggleton P, Michalak M. Calreticulin for better or for worse, in sickness and in health, until death do us part. Cell Calcium 2013 54 126-131.